Patent US629133A successfully refreshed from Google Patents.
US5773019A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Implantable controlled release device to deliver drugs directly to an internal portion of the body
Assignee: University of Kentucky Research Foundation
•
Filing: 1995-09-27
•
Granted: 1998-06-30
•
Expires: 2015-09-27
Abstract
Abstract A simple and implantable sustained release drug delivery device with an inner core containing an effective amount of a low solubility agent covered by a non-bioerodible polymer coating layer that is permeable to the low solubility agent is disclosed. A method for treating a mammal to obtain a desired local or systemic physiological or pharmacological effect by surgically implanting such a sustained release drug delivery device into a mammal in need of treatment is also disclosed.
Inventors
- 👤 Paul Ashton
- 👤 Paul A. Pearson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 18:31
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051; A61F; A61F9/00; A61F9/0008; A61F9/0017; A61M; A61M31/00; A61M31/002; A61P; A61P27/00; A61P27/02
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
82 words
A sustained release drug delivery device comprising: an inner core comprising an effective amount of a low solubility agent selected from the group consisting of immune response modifiers, corticosteroids, angiostatic steroids, anti-parasitic agents, anti-glaucoma agents, antibiotics, anti-sense compounds, differentiation modulators, anti-viral agents, anti-cancer agents, nonsteroidal anti-inflammatory agents, and low solubility codrugs; and a non-bioerodible polymer coating layer, the polymer layer being permeable to the low solubility agent, wherein the polymer coating layer covers the inner core and is essentially non-release rate limiting.
Claim 2
Dependent Claim
82 words
A sustained release drug delivery device comprising: an inner core comprising an effective amount of a low solubility agent selected from the group consisting of immune response modifiers, corticosteroids, angiostatic steroids, anti-parasitic agents, anti-glaucoma agents, antibiotics, anti-sense compounds, differentiation modulators, anti-viral agents, anti-cancer agents, nonsteroidal anti-inflammatory agents, and low solubility codrugs; and a non-bioerodible polymer coating layer, the polymer layer being permeable to the low solubility agent, wherein the polymer coating layer covers the inner core and is essentially non-release rate limiting.
Claim 3
Dependent Claim
28 words
The device according to claim 1, wherein the polymer coating layer holds the inner core in correct anatomic position and essentially prevents disintegration of the low solubility agent.
Claim 4
Dependent Claim
34 words
The device according to claim 2, wherein the polymer coating layer essentially reduces interaction between the low solubility agent in the inner core and proteinaceous components in surrounding bathing fluid to prevent enhanced release.
Claim 5
Dependent Claim
31 words
The device according to claim 1, wherein the low solubility agent is selected from the group consisting of cyclosporine A, trans-retinoic acid, cis-retinoic acid, other retinoids, and low solubility anti-sense compounds.
Claim 6
Dependent Claim
14 words
The device according to claim 1, wherein the polymer comprises a heat-treated polyvinyl alcohol.
Claim 7
Dependent Claim
11 words
The device according to claim 1, wherein the polymer is silicone.
Claim 8
Dependent Claim
12 words
The device according to claim 1, further comprising a means for attachment.
Claim 9
Dependent Claim
32 words
The device according to claim 4, wherein the means for attachment is selected from the group consisting of an extension of the polymer coating layer, a backing member or a support ring.
Claim 10
Dependent Claim
26 words
The device according to claim 1, wherein the inner core consists essentially of an effective amount of a low solubility agent or a pharmaceutically acceptable salt.
Claim 11
Dependent Claim
16 words
The device according to claim 1, wherein the polymer coating layer completely covers the inner core.
Claim 12
Dependent Claim
46 words
The device according to claim 1, consisting essentially of: the inner core comprising an effective amount of the low solubility agent; and the non-bioerodible polymer coating layer, the polymer layer being permeable to the low solubility agent, wherein the polymer coating layer covers the inner core.
Claim 13
Independent Claim
115 words
A method for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect comprising: surgically implanting a sustained release drug delivery device into a mammal in need of such treatment, the drug delivery device comprising: an inner core comprising an effective amount of a low solubility agent selected from the group consisting of immune response modifiers, corticosteroids, angiostatic steroids, anti-parasitic agents, anti-glaucoma agents, antibiotics, anti-sense compounds, differentiation modulators, anti-viral agents, anti-cancer agents, nonsteroidal anti-inflammatory agents, and low solubility codrugs; and a non-bioerodible polymer coating layer, the polymer layer being permeable to the low solubility agent, wherein the polymer coating layer covers the inner core and is essentially non-release rate limiting.
Claim 14
Independent Claim
115 words
A method for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect comprising: surgically implanting a sustained release drug delivery device into a mammal in need of such treatment, the drug delivery device comprising: an inner core comprising an effective amount of a low solubility agent selected from the group consisting of immune response modifiers, corticosteroids, angiostatic steroids, anti-parasitic agents, anti-glaucoma agents, antibiotics, anti-sense compounds, differentiation modulators, anti-viral agents, anti-cancer agents, nonsteroidal anti-inflammatory agents, and low solubility codrugs; and a non-bioerodible polymer coating layer, the polymer layer being permeable to the low solubility agent, wherein the polymer coating layer covers the inner core and is essentially non-release rate limiting.
Claim 15
Dependent Claim
28 words
The device according to claim 12, wherein the polymer coating layer holds the inner core in correct anatomic position and essentially prevents disintegration of the low solubility agent.
Claim 16
Dependent Claim
34 words
The method according to claim 13, wherein the polymer coating layer essentially eliminates interaction between the low solubility agent in the inner core and proteinaceous components in surrounding bathing fluid to prevent enhanced release.
Claim 17
Dependent Claim
15 words
A method according to claim 12, wherein the device is surgically implanted within the eye.
Claim 18
Dependent Claim
23 words
A method according to claim 12, wherein the device is attached to an intraocular lens or a haptic extending from the intraocular lens.
Claim 19
Dependent Claim
19 words
A method according to claim 12, wherein the treatment is for uveitis, age related macular degeneration, and cytomegalovirus retinitis.
Claim 20
Dependent Claim
24 words
A method according to claim 12, wherein the polymer coating layer is essentially insoluble and inert in body fluids and compatible with eye tissues.
Claim 21
Dependent Claim
29 words
A method according to claim 12, wherein the agent is selected from the group consisting of cyclosporine A, trans-retinoic acid, cis-retinoic acid, other retinoids, and low solubility anti-sense compounds.
Claim 22
Dependent Claim
18 words
A method according to claim 12, wherein the sustained release device is surgically implanted at a desired location.
Claim 23
Dependent Claim
25 words
A method according to claim 12, wherein the sustained release device delivers an effective amount of the low solubility agent for at least 5 years.
Claim 24
Dependent Claim
25 words
A method according to claim 12, wherein the sustained release device delivers an effective amount of the low solubility agent for at least 10 years.
References Cited (Backward Citations)
US3416530A
Cited
US3832252A
Cited
US3845201A
Cited
US3870791A
Cited
US4300557A
Cited
US4309996A
Cited
US4309776A
Cited
US4942035A
Cited
US4808353A
Cited
US4973304A
Cited
US4649047A
Cited
US5229128A
Cited
US5137728A
Cited
US4923699A
Cited
US5128144A
Cited
US5164188A
Cited
US5091185A
Cited
US5156851A
Cited
US5232708A
Cited
US5378475A
Cited
US5178635A
Cited
US5342620A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-06-29 | 2001-12-29 | 2002-06-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-06-29 | 2005-12-29 | 2006-06-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-06-29 | 2009-12-29 | 2010-06-30 | $7700.00 | Window Closed / Lapsed |